Valuation: Seres Therapeutics, Inc.

Market Cap 45.13M 38.98M 36.63M 33.31M 62.63M 4.32B 63.67M 429M 168M 2.16B 169M 166M 7.18B P/E 2026 *
-1.29x
P/E 2027 * -0.92x
Enterprise Value 45.13M 38.98M 36.63M 33.31M 62.63M 4.32B 63.67M 429M 168M 2.16B 169M 166M 7.18B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 165x
Free-Float
88.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+1.34%
1 week-6.78%
Current month-6.00%
1 month-16.70%
3 months-40.58%
6 months-46.40%
Current year-69.49%
1 week 4.44
Extreme 4.44
5.05
1 month 4.44
Extreme 4.44
5.69
Current year 4.44
Extreme 4.44
16.42
1 year 4.44
Extreme 4.44
29.98
3 years 4.44
Extreme 4.44
73.4
5 years 4.44
Extreme 4.44
233.8
10 years 4.44
Extreme 4.44
770
Manager TitleAgeSince
Chief Executive Officer 70 2026-03-01
Chief Executive Officer 58 2025-07-31
President 51 2026-03-01
Director TitleAgeSince
Chairman 70 2026-03-01
Director/Board Member 50 2019-01-14
Director/Board Member 80 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

General Counsel

7,500 0.0774%
7/8/26 Free

Director

6,500 0.0671%
7/8/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
+1.34%-6.78%-72.80%-93.95% 45.13M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.18%+1.07%+40.20%+175.65% 26.37B
Weighted average by Cap. -1.09%+0.55%+50.21%+164.95%

Financials

2026 *2027 *
Net sales 13.8M 11.92M 11.2M 10.18M 19.15M 1.32B 19.46M 131M 51.3M 661M 51.8M 50.68M 2.2B 274K 236K 222K 202K 380K 26.15M 386K 2.6M 1.02M 13.1M 1.03M 1M 43.52M
Net income -37.49M -32.38M -30.43M -27.67M -52.02M -3.58B -52.88M -357M -139M -1.8B -141M -138M -5.97B -78.95M -68.19M -64.08M -58.28M -110M -7.55B -111M -751M -294M -3.78B -296M -290M -12.56B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26-08-14 US$4.540 +1.34% 37,281
26-08-13 US$4.480 -5.08% 81,900
26-08-12 US$4.720 +1.72% 45,371
26-08-11 US$4.640 -7.20% 84,677
26-08-10 US$5.000 +2.67% 84,595
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.540USD
Average target price
17.00USD
Spread / Average Target
+274.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock